Mark J. Gergen
2023 - Poseida Therapeutics
In 2023, Mark J. Gergen earned a total compensation of $3.8M as Chief Executive Officer, President and Chairman at Poseida Therapeutics, a 13% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $336,420 |
|---|---|
| Option Awards | $1,413,936 |
| Salary | $611,667 |
| Stock Awards | $1,442,285 |
| Other | $13,710 |
| Total | $3,818,018 |
Gergen received $1.4M in stock awards, accounting for 38% of the total pay in 2023.
Gergen also received $336.4K in non-equity incentive plan, $1.4M in option awards, $611.7K in salary and $13.7K in other compensation.
Rankings
In 2023, Mark J. Gergen's compensation ranked 202nd out of 2,978 executives tracked by ExecPay. In other words, Gergen earned more than 93.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 202 out of 2,978 | 93rd |
Division Manufacturing | 109 out of 1,637 | 93rd |
Major group Chemicals And Allied Products | 71 out of 906 | 92nd |
Industry group Drugs | 70 out of 869 | 92nd |
Industry Biological Products, Except Diagnostic Substances | 26 out of 211 | 88th |
Source: SEC filing on April 25, 2024.
Gergen's colleagues
We found two more compensation records of executives who worked with Mark J. Gergen at Poseida Therapeutics in 2023.